Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 74

Sort by

Sort Order Select

Journal Articles

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Deepu Madduri, MD, Saad Z. Usmani, MD, Sundar Jagannath, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M Schecter, MD, Sen Zhuang, Jeffrey R. Infante, MD, Syed Rizvi, Xiaohu (Frank) Fan, MD PhD, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD

Blood (2019) 134 (Supplement_1): 577.

https://doi.org/10.1182/blood-2019-121731

Published: 2019

Journal Articles

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management

Blood (2019) 134 (Supplement_1): 4458.

https://doi.org/10.1182/blood-2019-126022

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Joanna S. Yi, MD, Tiffany Chambers, MPH, Kelly D Getz, Tamara P. Miller, MDMSc, Evanette Burrows, MPH, Marla Daves, MD, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Richard Aplenc, MD PhD, Karen R. Rabin, MD PhD, Maria Monica J. Gramatges, MD PhD

Blood (2019) 134 (Supplement_1): 3814.

https://doi.org/10.1182/blood-2019-123992

Published: 2019

Journal Articles

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Daria Gaut, MD, Kevin Tang, BS, BA, Myung Sim, PhD, Tuyen Duong, Joshua Sasine, MD PhD, Patricia A. Young, MD

Blood (2019) 134 (Supplement_1): 4109.

https://doi.org/10.1182/blood-2019-122195

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Blood (2019) 134 (Supplement_1): 1947.

https://doi.org/10.1182/blood-2019-126208

Published: 2019

Journal Articles

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Hamza Hashmi, MD, Alicia Darwin, Christina A Bachmeier, PharmD, Julio Chavez, Bijal Shah, MD, Javier Pinilla Ibarz, MD PhD, Taiga Nishihori, MD, Farhad Khimani, MD, Aleksandr Lazaryan, MDPhDMPH, Hien D. Liu, MD, Marco L. Davila, MD PhD, Frederick L. Locke, MD, Michael D. Jain, MD PhD

Blood (2019) 134 (Supplement_1): 1612.

https://doi.org/10.1182/blood-2019-126148

Published: 2019

Journal Articles

Evaluation of Pulmonary Function in Patient with Transfusion Dependent Beta Thalassemia with Severe Iron Overload

Mohamed A Yassin, MBBS, MSc, Mushtaq Ahmad, MD, Shehab Mohamed, MD, Khadra S Yassin, BSC, Abdulqadir Jeprel Nashwan, BSN, MSN, Vincenzo Desanctis, MD PhD, Ashraf Tawfiq Soliman, MD PhD

Blood (2019) 134 (Supplement_1): 4818.

https://doi.org/10.1182/blood-2019-121828

Published: 2019

Journal Articles

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study

Richard T. Maziarz, MD, Stephen J. Schuster, MD, Vadim V. Romanov, MD MPhil, FFPM, Elisha S. Rusch, PhD, James Signorovitch, PhD, Solveig G. Ericson, MD PhD, David G. Maloney, MD PhD, Frederick L. Locke, MD

Blood (2018) 132 (Supplement 1): 4183.

https://doi.org/10.1182/blood-2018-99-118595

Published: 2018

Journal Articles

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 96.

https://doi.org/10.1182/blood-2018-99-120013

Published: 2018

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD

Blood (2018) 132 (Supplement 1): 763.

https://doi.org/10.1182/blood-2018-99-119786

Published: 2018

Journal Articles

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Su Qu, Liqing Kang, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Shuang Yan, Yong Liu, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MDPhD, Lei Yu, ChengCheng Fu

Blood (2018) 132 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2018-99-117964

Published: 2018

Journal Articles

A Single Institution's Adherence to Heparin-Induced Thrombocytopenia and Thrombosis Testing Guidelines

Kristine Gade, MD BS, Jack Melson, MD, Alex Jepsen, MD, Surabhi Palkimas, PharmD, Bethany Horton, PhD, Hillary S. Maitland, MD MS

Blood (2018) 132 (Supplement 1): 4720.

https://doi.org/10.1182/blood-2018-99-117132

Published: 2018

Journal Articles

Drug Value Along the Treatment Continuum in Hodgkin Lymphoma

Ohad Oren, MD

Blood (2018) 132 (Supplement 1): 4728.

https://doi.org/10.1182/blood-2018-99-109702

Published: 2018

Journal Articles

Targeting T Cell Bioenergetics By Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells to Prevent Graft-Versus-Host Disease While Maintaining Antitumor Immunity

Zachariah McIver, DO, PhD, Rebecca Blevins, BS, Benjamin Coe, BS, Jason Grayson, PhD

Blood (2017) 130 (Supplement 1): 4456.

https://doi.org/10.1182/blood.V130.Suppl_1.4456.4456

Published: 2017

Journal Articles

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Stephen Couban, MDBSc, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, MD PhD, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Ian Templeton, Francesco Passamonti

Blood (2017) 130 (Supplement 1): 4179.

https://doi.org/10.1182/blood.V130.Suppl_1.4179.4179

Published: 2017

Journal Articles

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Dipenkumar Modi, MD, Wei Chen, Hyejeong Jang, Abhinav Deol, MD, Lois Ayash, MD, Asif Alavi, MD, Divaya Bhutani, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2017) 130 (Supplement 1): 3275.

https://doi.org/10.1182/blood.V130.Suppl_1.3275.3275

Published: 2017

Journal Articles

Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

Aneel Paulus, MD, Sharoon Akhtar, MPhil, Yamima Bashir, MBBS, Shumail M. Paulus, MBBS, Hassan Yousaf, Vivek Roy, MD, Sikander Ailawadhi, MD, Stephen Ansell, MD PhD, Thomas E. Witzig, MD, Asher A. Chanan-Khan, MD

Blood (2016) 128 (22): 3018.

https://doi.org/10.1182/blood.V128.22.3018.3018

Published: 2016

NARROW

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells

Fever Characteristics Associated with Toxicity and Outcome after Anti-CD19 CAR T-Cell Therapy for Aggressive Lymphoma

Evaluation of Pulmonary Function in Patient with Transfusion Dependent Beta Thalassemia with Severe Iron Overload

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

A Single Institution's Adherence to Heparin-Induced Thrombocytopenia and Thrombosis Testing Guidelines

Drug Value Along the Treatment Continuum in Hodgkin Lymphoma

Targeting T Cell Bioenergetics By Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells to Prevent Graft-Versus-Host Disease While Maintaining Antitumor Immunity

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Transaminase Elevation As a Marker of Liver GVHD Is Associated with Poor Survival Among Allogeneic Stem Cell Transplant Recipients

Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only